Access
Email Verification
Agenda 2022
DAY 1: THURSDAY, 15 SEPTEMBER, 2022
0830 - 0930 REGISTRATION AND MORNING REFRESHMENTS
0930 - 0940 OPENING ADDRESS
0940 - 1010 LEVERAGING PRIVATE PUBLIC PARTNERSHIPS IN COVID-19 PANDEMIC RESPONSE
- International co-operation and global solidarity
- Leverage private public partnership in vaccines development
- Rules need to be set now to manage procurement for equitable access
Anh Wartel
International Vaccine Institute
International Vaccine Institute
1010 - 1040 CEPI's 100 DAYS AMBITION - HOW DO WE DEVELOP A VACCINE IN 100 DAYS
- Building readiness for the next health threat
- Challenges to manufacturing vaccines
- Scaling to billions
Ramin Sabet-Azad
CEPI
CEPI
1040 - 1100 MORNING COFFEE BREAK IN EXHIBIT AREASPONSORED BY NOF EUROPE GMBH
1100 - 1130 RAPID RESPONSE VACCINE PLATFORMS FOR FUTURE PANDEMICS: CONSIDERATIONS FOR LOW AND MIDDLE-INCOME COUNTRIES (LMICS)
- Several new vaccine platforms have been utilized to develop COVID-19 vaccine candidates
- Intervention Target Product Profiles have been developed to help guide developers with respect to COGs/Pricing, storage requirements, and other key product parameters
- Goal: Review emerging vaccine platforms to assess their potential to address the requirements for LMICs and applicability to future pandemic response
Ajoy Chakrabarti
Bill & Melinda Gates Foundation
Bill & Melinda Gates Foundation
1130 - 1200 DEVELOPMENT AND PRECLINICAL TESTING OF A NOVEL SELF-ASSEMBLING T-CELL VACCINE FOR COVID-19
- Presentation of the VaxCelerate platform developed with US DoD support to address pandemic and emerging infectious diseases
- Preclinical testing of the VaxCelerate platform for Lassa Fever and COVID-19
- Planning for first in human testing of the self-assembling vaccine for COVID-19
Patrick Reeves
Mass General Brigham Incorporated
Mass General Brigham Incorporated
1200 - 1330 NETWORKING LUNCH & VISIT VACCINE TECHNOLOGY EXHIBITION
1330 - 1400 CELL-FREE SYNTHETIC SYSTEMS FOR SCALABLE AND TIMELY VACCINE MANUFACTURE
- Requirements for rapid scale-up and deployment of vaccines has accelerated the maturation of cell-free systems as an approach for commercial biologics supply
- Opportunities afforded by such an approach as well as the challenges to be overcome to improve its more widespread adoption
- Case studies to illustrate the points raised and share learnings from the work at CPI
Philip Probert
Centre for Process Innovation Limited
Centre for Process Innovation Limited
1400 - 1430 DEVELOPMENT OF AN AUTOMATED MICROSCALE SCREENING PLATFORM FOR GLYCOCONJUGATE VACCINE PRODUCTION
- Initial scale down using kla estimations and the product expression achieved at two scales
- Development of an automated microscale screening platform
- Results from the screening platform (strain comparison and media formulation)
Jasmin Samaras
UCL & VaxHub
UCL & VaxHub
1430 - 1500 COMPARISON OF 3 PRODUCTION SYSTEMS FOR VACCINE MANUFACTURING
- Corning Cell Staks 20 x CS10, and 16 x CS40
- Univercells fixed bed bioreactor: 2.7m² and 200m²
- iCELLis fixed bed bioreactor: 4 m²
Sabrina Pelz
IDT Biologika GmbH
IDT Biologika GmbH
1500 - 1530 AFTERNOON COFFEE BREAK IN EXHIBIT AREASPONSORED BY NEST SCIENTIFIC
1530 - 1600 UNLOCKING VACCINE MANUFACTURING POTENTIAL WITH NOVEL BIOPROCESSING TECHNOLOGY
- A single-use bioreactor for large-scale Vaccine production with Linear scalability, process Efficiency, and Affordability
- A Bioprocess technology that can be adapted for intensified production of Viral Vectors, Biosimilars, and Monoclonal Antibody
Tulip Nuwal
OmniBRx Biotechnologies Pvt. Ltd.
OmniBRx Biotechnologies Pvt. Ltd.
1600 - 1630 COMBINING EVOLUTIONARY ENGINEERING WITH PROCESS INTENSIFICATION FOR IMPROVED INFLUENZA HA-VLPS PRODUCTION IN STABLE INSECT CELLS
- Adaptive laboratory evolution of stable insect cells to hypothermic culture conditions - evolutionary engineering
- High-cell-density cultures using perfusion - process intensification
- Stable insect Sf9 cell lines for influenza HA-VLPs production
Ricardo Correia
iBET
iBET
1630 - 1700 WHICH SUGAR DO YOU WANT? ENGINEERING CHO CELLS FOR THE PRODUCTION OF RECOMBINANT PROTEINS WITH TAILOR-MADE GLYCOSYLATION
- High throughput targeted engineering of CHO cells for improved production of recombinant proteins
- Toolbox: 30+ cell lines for quick production of small quantities of glycovariants for screening for optimal glycoform
- Scalable production of the preferred glycovariant from stable and robust production cell line
Bjorn Voldborg
Technical University of Denmark
Technical University of Denmark
1700 - 1800 NETWORKING DRINKS RECEPTION
DAY 2: FRIDAY, 16 SEPTEMBER, 2022
0900 - 0930 MORNING REFRESHMENTS
0930 - 0940 OPENING ADDRESS
0940 - 1010 RESERVED PRESENTATION
1010 - 1040 MAKING HEALTHCARE MORE ACCESSIBLE
- Transforming biomanufacturing to make healthcare more accessible and affordable to patients globally
- Learn about C1-cells are a faster, more efficient, and affordable way to manufacture biologic vaccines & drugs
- Understanding vaccine and/or drug that is not accessible or affordable is 100% ineffective and health equity
Mark Emalfarb
Dyadic International, Inc.
Dyadic International, Inc.
1040 - 1110 NEXT GENERATION SARS COV-2 T-CELL VACCINE USING AN INTRANASAL NANOPARTICLE DELIVERY SYSTEM AND GENE BASED IMMUNODULATORS
- Elicits T-cell responses with the potential to last for more than 1 year
- Delivered intranasally to elicit local immunity in the airways and lungs, sites of viral entry and infection where first-line potent, long-term resident T cell memory responses are most critical
- Deliver a gene-based immunomodulator that stimulates trained innate immunity to ‘turbocharge’ potent and durable T cell memory responses to vaccination
Tom Tillett
MBF Therapeutics
MBF Therapeutics
1110 - 1130 MORNING COFFEE BREAK IN EXHIBIT AREASPONSORED BY ABZENA
1130 - 1200 GENOME EDITING OF AVIAN HERPES VIRUSES FOR RECOMBINANT VACCINE DEVELOPMENT
- Generation of trivalent HVT vectored vaccine using CRISPR/Cas9 system
- Efficacy testing of the trivalent recombinant vaccine
- CRISPR screening to identify essential/ non-essential genes for engineering of avian herpesvirus vaccines
Yongxiu Yao
The Pirbright Institute
The Pirbright Institute
1200 - 1230 ROLE OF PRODUCT DEVELOPMENT PARTNERSHIP IN ACCELERATING VACCINE DEVELOPMENT: EXPERIENCE FROM IVI’S TYPHOID PROGRAM
- PDPs play critical role to move the neglected disease vaccine agenda forward
- Multiple complex interrelationships affect vaccine development
- Experiences from 4 countries, 5 clinical trials from IVI’s typhoid program
Sushant Sahastrabuddhe
International Vaccine Institute
International Vaccine Institute
1230 - 1300 ADOPTION OF HTPD FOR VACCINES PROCESS DEVELOPMENT
- Leveraging automation and adopting High Throughput Process Development (HTPD)
- Learn about case studies, in both upstream and downstream process development applications
Sheng-Ching Wang
Merck & Co., Inc
Merck & Co., Inc
1300 - 1430 NETWORKING LUNCH & RAFFLE DRAW
Key topics for 2022:
- The fundamentals of new vaccine discovery and development
Understand biotech and pharmaceutical industry fundamentals and key market drivers for developing vaccinations from a global perspective. - Exploring new technologies in vaccine delivery for better immune responses
Look for new opportunities and make the clinical case for adopting new technology and techniques for vaccine delivery. - Latest research in genetically-engineered vaccinations and mRNA vaccine technologies
Explore new innovations and assess the latest results from tests and trials in biologically-engineered vaccinations and new advancements in DNA and messenger RNA vaccination technologies. - New developments in viral vectors, nucleic acid-based vaccines, and structural vaccinology
Future vaccination strategies and the latest advancements in viral vector-based applications for adapting structural viral vaccine design and development. - Advances in live-attenuated virus vaccines and lessons learnt from inactivated vaccines
Hear from leading vaccine developers and build on traditional vaccine approaches for cost-effective and proven methods for developing new vaccines. - Case studies and clinical trials and working with global vaccine manufacturers
Gain insight from leading manufacturers and implement strategies that others in the industry use to ensure successful vaccine delivery.
Sponsorship Opportunities
Join us as a sponsor for this IQ International conference! Reach your target audience, limit competitor influence at the conference and become a keynote speaker, while sharing your company's solutions for this industry.
- Get registration discounts
- Enhance your brand awareness
- Additional marketing opportunities